Tvardi Therapeutics is trading 5.70% higher at $1.35 in pre-market on September 30, 2026; the reason for the move remains unclear. - Available reporting and company investor-relations updates show no new announcement; the latest located company release was September 24 and concerned preclinical data. - The broader market is near flat, offering no clear explanation for the gain. - The move follows a volatile week, but that alone does not establish a cause.